Articles From: Dangdang to Report Third Quarter 2014 Financial Results on November 25, 2014 to Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology Demonstrates ALD403 Effective in the Preventive Treatment of Migraine


2015/1/13
Daniel Drimmer Acquires Units of True North Commercial Real Estate Investment Trust Canada NewsWire /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED S TATES/ TORONTO , Jan.
Sign-up for Daniel Drimmer Acquires Units of True North Commercial Real Estate Investment Trust investment picks
CHARLOTTE, Mich.
Sign-up for Daniel Slater Joins Spartan Motors as President of Emergency Response investment picks
Daniels Corporate Advisory Co.
Sign-up for Daniels Corporate Advisory Co. Inc. Letter to Shareholders investment picks
2014/10/27
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0975081001&sourceType=1 http://media3.marketwire.com/logos/20140813-danier200.jpg TORONTO, ONTARIO --
Sign-up for Danier Leather Announces Re-Election of Directors investment picks
2014/10/27
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0974998001&sourceType=1 http://media3.marketwire.com/logos/20140813-danier200.jpg TORONTO, ONTARIO --
Sign-up for Danier Leather Reports Fiscal 2015 First Quarter Results investment picks
2015/1/15
ADVISORY, Jan.
Sign-up for Danish Deputy Prime Minister and Minister of Finance to Ring the Nasdaq Stock Market Closing Bell investment picks
2014/11/20
By Ruth Bender, Eyk Henning and Shayndi RaiceFresenius, Permira make joint bid German health-care group Fresenius SE & Co.
Sign-up for Danone gets bid for medical-nutrition business investment picks
2014/12/30
CHONGQING, China , Dec.
Sign-up for Daqo New Energy Corp. Announces Resolution Adopted at 2014 Annual General Meeting investment picks
2014/11/13
- Record-high quarterly polysilicon production volume of 1,748 MT in Q3 2014, up from 1,504 MT in Q2 2014 - Record-high quarterly polysilicon shipments of 1,598 MT in Q3 2014, up from 1,436 MT in Q2 2014 - Record-low polysilicon production cost of $13.05/kg in Q3 2014, down from $14.13/kg in Q2 2014; cash cost of $10.72/kg in Q3 2014, down from $11.48/kg in Q2 2014 - Non-GAAP gross margin of 31.7% - EBITDA of $16.4 million in Q3 2014, up from $15.2 million in Q2 2014 - Net income attributable to Daqo shareholders of $5.9 million, up from $4.5 million in Q2 2014 CHONGQING, China , Nov.
Sign-up for Daqo New Energy Corp. Announces Third Quarter 2014 Results investment picks
2014/11/28
CHONGQING, China , Nov.
Sign-up for Daqo New Energy Corp. to Hold Annual General Meeting on December 30, 2014 investment picks
2014/11/5
CHONGQING, China , Nov.
Sign-up for Daqo New Energy to Announce Third Quarter 2014 Results on November 13, 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G025592-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/11/5/11G025592/Logo1-1839417150.jpg RALEIGH, NC--(Marketwired - November 05, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2014 results.
Sign-up for DARA BioSciences Announces Third Quarter 2014 Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G025138-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/10/30/11G025138/Logo1-1480300049.jpg RALEIGH, NC--(Marketwired - October 31, 2014) - DARA BioSciences, Inc .
Sign-up for DARA BioSciences Continues to Support Patient Outreach and Education in Conjunction With Breast Cancer Awareness Month investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G029613-001&sourceType=1 http://www.marketwire.com/library/MwGo/2015/1/5/11G029613/Logo1-1000450577.jpg RALEIGH, NC--(Marketwired - January 06, 2015) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it has been granted a "barrier-to-innovation" waiver for certain product and establishment fees.
Sign-up for DARA BioSciences Granted Waiver of Product and Establishment Fees by the FDA investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G024874-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/10/28/11G024874/Logo1-516342230.jpg RALEIGH, NC--(Marketwired - October 29, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals with a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today petitioned the U.S. Food and Drug Administration (FDA) to amend the label for tamoxifen citrate and Soltamox ® (tamoxifen citrate), the only FDA-approved liquid bioequivalent of tamoxifen, by increasing the recommended duration of adjuvant therapy for women with estrogen receptor-positive breast cancer from five to 10 years.
Sign-up for DARA BioSciences Petitions FDA to Amend Label for Tamoxifen Citrate and Soltamox® to Extend Duration of Adjuvant Therapy to 10 Years investment picks
Actions Will Sharpen Focus on Operations and Guest Experience While Reducing Costs Plan Includes Senior Leadership Changes, Streamlining of Support and Operations Functions, and Closure of Corporate Aviation Department ORLANDO, Fla.
Sign-up for Darden Announces Leadership Changes And Strategic Actions investment picks
Darden Restaurants' stock (DRI) rose 1.3% in after-hours trade Tuesday, after the casual-dining restaurant chain reported better-than-expected fiscal second-quarter profit and sales.
Sign-up for Darden Restaurants' stock rises after beating profit, sales expectations investment picks
ORLANDO, Fla.
Sign-up for Darden Retains Korn Ferry For CEO Search investment picks
Company Names John O.
Sign-up for Darling Ingredients Inc. Announces Appointment Of New Chief Financial Officer investment picks
- Net income attributable to Darling of $14.3 million or $0.09 per diluted share; Pro Forma Adjusted EBITDA of $122.3 million - Strong cash generation in the third quarter with $138.3 million of net cash provided by operating activities; Cash EPS of $0.84 per diluted share - Feed Segment performance impacted by significant decline in fat prices worldwide - Fuel Segment performance reflects Diamond Green Diesel operating on 47 days during the quarter IRVING, Texas , Nov.
Sign-up for Darling Ingredients Inc. Reports Third Quarter 2014 Financial Results investment picks
IRVING, Texas , Dec.
Sign-up for Darling Ingredients Inc. To Benefit From Biodiesel Tax Credit investment picks
2015/1/20
Who doesn’t enjoy everything that comes with a “spa day”? Now you can experience a little taste of it on the go with DASANI DROPS Infusions- a new easy way to enhance your water with a splash of flavor to leave you refreshed.
Sign-up for DASANI® Presents DASANI DROPS® Infusions investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Dangdang to Report Third Quarter 2014 Financial Results on November 25, 2014 to Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology Demonstrates ALD403 Effective in the Preventive Treatment of Migraine
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent